HIV anti CD40 HIV5 PEP vaccine - EnnoDC
Alternative Names: HIV ANTI-CD40 HIV5-PEPLatest Information Update: 08 Oct 2024
Price :
$50 *
At a glance
- Originator Vaccine Research Institute
- Developer EnnoDC
- Class Recombinant fusion proteins; Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical HIV infections
Most Recent Events
- 26 Sep 2024 LinKinVax is now called EnnoDC
- 14 Mar 2022 LinKinVax plans to launch HIV vaccine for HIV infections (Prevention) by 2027 (LinKinVax pipeline, March 2022)
- 03 Feb 2022 LinKinVax entered an exclusive worldwide licensing agreement with Inserm Transfert to develop vaccine strategy for HIV, SARS-CoV-2, human papillomavirus-related cancers, and chlamydia infections